|
gptkbp:instanceOf
|
gptkb:protein
|
|
gptkbp:alternativeName
|
gptkb:CD279
PDCD1
|
|
gptkbp:associatedWith
|
gptkb:cancer
autoimmune diseases
chronic infections
|
|
gptkbp:blockadeSideEffect
|
immune-related adverse events
|
|
gptkbp:blockadeUsedFor
|
gptkb:immunotherapy
|
|
gptkbp:contains
|
IgV-like domain
|
|
gptkbp:discoveredBy
|
gptkb:Tasuku_Honjo
|
|
gptkbp:discoveredIn
|
1992
|
|
gptkbp:encodedBy
|
gptkb:PDCD1_gene
|
|
gptkbp:Entrez_Gene_ID
|
ENSG00000188389
|
|
gptkbp:expressedIn
|
gptkb:natural_killer_cells
gptkb:B_cells
gptkb:T_cells
monocytes
|
|
gptkbp:foundIn
|
humans
mice
|
|
gptkbp:fullName
|
gptkb:Programmed_cell_death_protein_1
|
|
gptkbp:function
|
gptkb:immunotherapy
inhibits T cell activity
|
|
gptkbp:gene
|
PDCD1
|
|
gptkbp:HGNC_ID
|
gptkb:HGNC:8765
|
|
gptkbp:inhibitedBy
|
cytokine production
T cell proliferation
T cell cytotoxicity
|
|
gptkbp:inhibitionLeadsTo
|
enhanced immune response
|
|
gptkbp:ligand
|
gptkb:PD-L2
PD-L1
|
|
gptkbp:locatedOnChromosome
|
gptkb:2q37.3_(human)
|
|
gptkbp:mechanismOfAction
|
inhibitory signaling via ITIM and ITSM motifs
|
|
gptkbp:OMIM
|
600244
|
|
gptkbp:PDB
|
3RRQ
|
|
gptkbp:phosphorylates
|
Y223
Y248
|
|
gptkbp:regulates
|
immune tolerance
peripheral tolerance
|
|
gptkbp:role
|
gptkb:immunotherapy
|
|
gptkbp:structure
|
type I transmembrane protein
|
|
gptkbp:target
|
gptkb:camrelizumab
gptkb:sintilimab
gptkb:tislelizumab
gptkb:toripalimab
gptkb:pembrolizumab
gptkb:cemiplimab
gptkb:nivolumab
|
|
gptkbp:UniProtID
|
Q15116
|
|
gptkbp:bfsParent
|
gptkb:Opdivo
gptkb:immunoglobulin_superfamily
gptkb:Camrelizumab
gptkb:Nivolumab
gptkb:Sintilimab
gptkb:Tislelizumab
gptkb:Toripalimab
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
PD-1
|